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Background: Acute lung injury (ALI) is characterized by a pro-coagulant state. Heparin is an anticoagulant with
anti-inflammatory properties. Unfractionated heparin has been found to be protective in experimental models of
ALI. We hypothesized that an intravenous therapeutic dose of unfractionated heparin would favorably influence
outcome of critically ill patients diagnosed with ALI.
Methods: Patients admitted to the Intensive Care Unit (ICU) of a tertiary referral center in the Netherlands between
November 2004 and October 2007 were screened. Patients who developed ALI (consensus definition) were
included. In this cohort, the impact of heparin use on mortality was assessed by logistic regression analysis in a
propensity matched case–control design.
Results: Of 5,561 admitted patients, 2,138 patients had a length of stay > 48 hours, of whom 723 were diagnosed
with ALI (34%), of whom 164 received intravenous heparin. In a propensity score adjusted logistic regression
analysis, heparin use did not influence 28-day mortality (odds ratio 1.23 [confidence interval 95% 0.80–1.89],
nor did it affect ICU length of stay.
Conclusions: Administration of therapeutic doses of intravenous unfractionated heparin was not associated with
reduced mortality in critically ill patients diagnosed with ALI. Heparin treatment did not increase transfusion
requirements. These results may help in the design of prospective trials evaluating the use of heparin as adjunctive
treatment for ALI.
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Acute lung injury (ALI), and its more severe form Acute
Respiratory Distress Syndrome (ARDS), are character-
ized by an exaggerated pulmonary pro-inflammatory and
pro-coagulant response of the host against some form of
insult. In sepsis, activation of coagulation as well as* Correspondence: j.j.hofstra@amc.uva.nl
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reproduction in any medium, provided the ordefective anticoagulant pathways and inhibition of fi-
brinolysis all contribute to systemic coagulopathy [1].
Similar disturbances in coagulation and fibrinolysis have
been found locally in models of ALI [2-4] and in lungs
of patients with ALI/ARDS [5,6]. There is evidence that
this coagulopathy contributes to pulmonary inflamma-
tion [7,8], as the extent of coagulopathy is independently
associated with adverse clinical outcomes in patients
with ALI/ARDS [8,9]. As such, the pathogenesis of ALI/
ARDS shares many similarities to sepsis [5,6] independ-
ent of the occurrence of sepsis [8]. Mechanical ventila-
tion also induces fibrin deposition in the lung, thereby
contributing to lung injury [8]. Infusion of recombinantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mortality in patients with severe sepsis in a large phase
III clinical trial [10], although this was offset by a re-
cently finished trial of patients with septic shock [11]. A
non-randomized subgroup analysis showed that APC
was particularly effective in patients who presented with
severe community–acquired pneumonia as the source of
sepsis, although these findings were not confirmed in a
clinical trial of sepsis patients with a low risk of death
[12] or the recently finished trial of patients with septic
shock [11]. The beneficial effect of APC in patients with
severe sepsis observed in the PROWESS trial could, at
least partially, be attributed to the effects of APC on
lung coagulation [13,14]. A retrospective cohort study
suggested that early administration of heparin is of
benefit in patients diagnosed with septic shock [15], al-
though this was not confirmed by a prospective clinical
trial [16].
Studies evaluating the effect of anticoagulant therapy
in ALI, mostly in experimental settings, are promising
[17,18]. Animal studies have demonstrated that adminis-
tration of heparins, APC, antithrombin (AT), tissue
factor–factor VIIa (TF–FVIIa) pathway inhibitors,
plasminogen activators and thrombomodulin can attenu-
ate pulmonary coagulopathy, reduce lung injury and/or
improve oxygenation [19].
Besides its anticoagulant effects, unfractionated hep-
arin has been shown to have a wide range of anti-
inflammatory and immunomodulatory effects [20-22].
Infusion of heparin was found to limit lung injury in
endotoxemic swine [23] and mice [24] and reduced pul-
monary fibrin depositions in a combined model of
smoke inhalation and lung injury in sheep, thereby im-
proving oxygenation [25]. In a rat model of acute lung
injury, heparin was found to have positive effects
through inhibiting nitric oxide synthase [26]. Further,
low molecular weight heparin reduced hyperoxia-
induced lung injury in mice through protein kinase
interactions [27]. In a clinical study, nebulized heparin
was found to significantly reduce activation of coagula-
tion in the lungs of ALI patients [28], further underlin-
ing the hypothesis that unfractionated heparin could
favorably influence outcome of ALI.
A significant subset of critically ill patients with ALI/
ARDS receives heparin early after admission to the ICU
[15]. Indications for heparin include respiratory insuffi-
ciency due to myocardial infarction, (suspected) venous
thromboembolism, atrial fibrillation and coumarin deriv-
ate treatment prior to ICU admission. Another indication
for heparin treatment is the use of renal replacement
therapy. Given the anticoagulant and anti-inflammatory
properties of heparin, we hypothesized that early heparin
is associated with reduced mortality among patients diag-
nosed with ALI/ARDS. Therefore, we evaluated theimpact of systemically administered therapeutic dose of
heparin on outcome in ALI patients in terms of mortality
as well as length of ICU stay.
Methods
Design
This is a nested case control study design, derived from
a retrospective cohort of ALI/ARDS patients [29]. The
study was approved by the Medical Ethics Committee of
the Academic Medical Center, Amsterdam, The Nether-
lands (reference 08.17.0964), who waived the require-
ment for individual informed consent in view of the
retrospective nature of this research.
Patient population
Using an electronic patient data monitoring system, all
patients with a first admission to the mixed medical-
surgical Intensive Care ward of a tertiary referral center in
the Netherlands from 1 November 2004 until 1 October
2007 were reviewed and screened. Patients who devel-
oped ALI (consensus definition) were included. In order
to determine the effect of heparin on patients who de-
velop ALI while being on the ICU, patients with a length
of stay shorter than 48 hours were excluded.
ALI was defined using the consensus definition of ALI:
new onset hypoxemia or deterioration, demonstrated by
a PaO2/FiO2 < 300 mmHg, with bilateral pulmonary
changes, in the absence of cardiogenic pulmonary edema
[30]. Pulmonary edema was diagnosed as being of car-
diogenic origin if the pulmonary arterial occlusion pres-
sure was >18 mmHg. In the absence of pulmonary
artery wedge catheter measurements, cardiac failure was
diagnosed if two of the following were present: central
venous pressure >15 mmHg, a history of heart failure or
valve dysfunction, ejection fraction <45% as estimated by
echocardiogram, or a positive fluid balance. The prob-
ability of cardiogenic pulmonary edema was scored by
two physicians independently on a scale of 1–4 (APJV
and NPJ) [31]. Chest radiographs were scored for the
presence of new onset bilateral interstitial abnormalities
by two independent physicians who were blinded to the
predictor variables. When interpretation differed, chest
radiograph and the description by the radiologist were
reviewed and discussed until consensus was reached.
Use of heparin was scored when patients received hep-
arin within 48 hours of diagnosis of AL/ARDS.
Patient data collection
All data was collected from our hospital patient data-
base. We collected the APACHE II score, length of ICU
stay and mortality. Potential ALI risk factors were scored
as positive when present 48 hours prior to onset of ALI,
including trauma, elective and emergency surgery, lung
contusion, aspiration, massive transfusion, pancreatitis,
Figure 1 Flowchart of patients diagnosed with acute lung
injury. Abbreviations; ALI = acute lung injury, ARDS= acute
respiratory distress syndrome.
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port measures requiring the use of inotropic or vaso-
pressor support were also scored.
Co-interventions that may influence outcome of ALI
were scored, including mechanical ventilation with tidal
volumes ≤ 8 ml/kg [32], restrictive fluid strategy (net
fluid balance in the first 7 days < 0 ml) [33], use of APC
[11] and use of steroids (>300 mg hydrocortisone per
day or the equivalent) [34]. Co-morbidities that influ-
ence use of heparin were scored, including myocardial
infarction, surgery and hematologic malignancy. Labora-
tory parameters scored on admission included platelet
count, prothrombin time (PT) and activated partial
thrombin time (aPTT).
Outcome measures
The primary outcome measure was mortality over
28 days. Secondary outcome variables included 90 day
mortality. Mortality data was cross-checked with the
Dutch Civil Registry. Safety of heparin administration
was assessed by comparing the need for allogeneic blood
transfusion.
Statistical analysis
Continuous variables are expressed as mean and stand-
ard deviation or medians and interquartile ranges de-
pending on distribution. Categorical variables are
expressed as n (%). Comparison between groups was
done with Student’s t-test or Mann–Whitney U test de-
pending on distribution. Categorical variables were com-
pared with the Chi-square test or Fisher’s exact test.
Cases were defined as patients who died within 28 days
of admission to the ICU. Cases were matched to con-
trols using propensity analysis [35,36]. Propensity score
was calculated by a multivariable logistic regression
model with heparin as the dependent variable, while all
other covariates related to mortality were included as in-
dependent variables. Covariates included age, sex, APA-
CHE II score, pre-existing medical condition (trauma,
sepsis, aspiration, pancreatitis, pneumonia, massive
transfusion), recent surgical history, respiratory failure
requiring mechanical ventilation, cardiovascular failure
requiring inotropic/vasopressor support and co-
interventions for ALI (use of APC or steroids, limited
tidal volume ventilation, restrictive fluid strategy). The
joint probability of these covariates to predict heparin
use is used to match cases with controls in a 1 to 3 fash-
ion, to control for confounding and bias due to non-
random selection of patients. We considered there might
be a causal relation between heparin treatment and
APACHE II score as both may occur within the 24 hours
following admission, therefore we calculated propensity
scores both with and without using the APACHE II
score in our model.Heparin use related to 28 days mortality as well as to
90 days mortality was investigated using conditional lo-
gistic regression. As effects of heparin may actually re-
flect effects related to a prolonged aPTT, comparisons
were repeated between patients with an aPTT of 45 sec-
onds or more and an aPTT of less than 45 seconds,
using a mixed ANOVA model for repeated measures
(4 measurements). Furthermore, we used a Cox pro-
portional hazards model with 28-day mortality as the
dependant variable and heparin use and propensity
scores as covariates, in order to estimate the relative
impact of heparin use on 28-day all-cause mortality.
Statistical analysis was conducted with SPSS version
16.0 (SPSS Inc., Chicago, IL, USA).Results
Patient populations
During the screening period, 5,561 patients were admit-
ted to our ICU. Of these, 398 patients were re-admis-
sions, 288 died within 48 hours and 2,737 were
discharged from the ICU within 48 hours, leaving 2,138
patients for screening of the presence of ALI (Figure 1).
Of these, 1,415 patients did not meet ALI criteria,
leaving 723 patients for analysis. The inter observer
agreement for the diagnosis of ALI was good (weighted
kappa 0.61).
Of the 723 patients, 164 patients received therapeutic
dose intravenous heparin. Baseline characteristics of the
(unmatched) patients are shown in Table 1. Outcome
did not differ between unmatched patient groups.
Groups were unbalanced with respect to age, APACHE
II score and type of admission diagnosis.
Table 1 Patient characteristics and outcome of unmatched ALI patients
No Heparin n= 559 Heparin n = 164 p value
Age, mean (SD) 59 (17) 63 (14) 0.003
Male,% (n) 70 (389) 63 (103) 0.10
APACHE II score, mean (SD) 17.8 (6.9) 19.8 (6.5) 0.001
Medical patients,% (n) 60 (334) 71 (117) 0.007
Surgery elective,% (n) 23 (128) 19 (31) 0.28
Surgery emergency,% (n) 17 (97) 7 (16) 0.02
Medical condition
Multiple Trauma,% (n) 8 (43) 2 (3) 0.007
Sepsis,% (n) 21 (115) 18 (29) 0.42
Diabetes,% (n) 14 (81) 16 (27) 0.53
Liver Failure,% (n) 3 (14) 2 (4) 0.96
Hematological malignancy,% (n) 6 (35) 2 (3) 0.03
Aspiration,% (n) 5 (26) 4 (6) 0.59
Pancreatitis,% (n) 2 (12) 2 (4) 0.82
Pneumonia,% (n) 23 (129) 10 (17) < 0.001
COPD 11 (62) 14 (23) 0.31
Auto immune disease,% (n) 6 (34) 9 (15) 0.17
Previous Myocardial infarction,% (n) 13 (72) 40 (66) < 0.001
Immune Compromised,% (n) 11 (61) 6 (10) 0.07
Massive Transfusion,% (n) 14 (78) 12 (19) 0.43
Life support measures
Respiratory failure (MV) ,% (n) 93 (519) 95 (156) 0.42
Cardiovascular failure (MI) ,% (n) 13 (72) 40 (66) <0.001
Co interventions
Activated Protein C,% (n) 4 (24) 1 (1) 0.02
Stress dose steroids,% (n) 42 (233) 46 (76) 0.29
Protective mechanical ventilation (<8 ml/kg) ,% (n) 54 (304) 55 (91) 0.29
Restrictive fluid strategy (net fluid balance first 7 days≤ 0 ml) ,% (n) 36 (203) 35 (58) 0.82
Outcome
28 days mortality,% (n) 24 (134) 30 (50) 0.09
90 days mortality,% (n) 32 (181) 39 (64) 0.11
ICU-stay, median (IQR) 7 (4–13) 7 (4–13) 0.59
Hospital-stay, median (IQR) 20 (11–38) 18 (8–37) 0.13
APACHE=Acute Physiology and Chronic Health Evaluation, COPD= chronic obstructive pulmonary disease, IQR= interquartile range, MI=myocardial infarction,
MV=mechanical ventilation, SD= standard deviation.
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Using logistic regression analysis, risk factors for 28-day
mortality were determined, shown in Table 2. As
expected, old age and high APACHE II scores were risk
factors for mortality in ALI patients, whereas undergo-
ing elective surgery protected against mortality. Dia-
betes, liver failure, autoimmune disease and a
compromised immune state were risk factors for mor-
tality in this cohort. Of interest, cardiovascular failure
did not contribute to mortality in ALI patients. Appli-
cation of limited tidal volume ventilation and therestrictive use of fluids were confirmed as protective
measures in this cohort of ALI patient. Interestingly, a
stress dose steroid regimen contributed to mortality in
this cohort of ALI patients. The covariates that signifi-
cantly contributed to outcome (including APACHE II
score) were used in a propensity-based analysis of the
risk to die of patients who had received heparin and
controls, which is shown in Table 3. Suitable propensity
matches were found for all patients receiving heparin.
Use of heparin did not alter mortality risk compared to
controls.
Table 2 Multivariate logistic regression analysis of covariates for the risk of 28-day mortality in ALI patients
OR (95% CI) P value*
Age 1.02 (1.00/1.03) 0.002
Male 1.39 (0.92/1.86) 0.13
APACHE II score 1.09 (1.06/1.12) < 0.001
Medical 1.94 (1.34/2.81) < 0.001
Surgery Elective 0.40 (0.25/0.65) < 0.001
Surgery Emergency 0.91 (0.57/1.45) 0.68
Medical conditions
Multiple Trauma 0.51 (0.22/1.15) 0.11
Sepsis 1.27 (0.84/1.90) 0.25
Diabetes 1.83 (1.18/2.83) 0.006
Liver Failure 3.82 (1.48/9.82) 0.006
Hematological malignancy 1.77 (0.89/3.49) 0.10
Aspiration 1.35 (0.63/2.91) 0.44
Pancreatitis 0.67 (0.19/2.38) 0.54
Pneumonia 1.14 (0.75/1.71) 0.55
COPD 1.26 (0.76/2.07) 0.37
Auto immune disease 1.95 (1.07/3.56) 0.03
Previous Myocardial infarction 1.25 (0.83/1.89) 0.29
Immune Compromised 1.69 (1.00/2.83) 0.05
Massive Transfusion 0.68 (0.40/1.16) 0.16
Life support measures
Respiratory failure at admission 1.00 (0.98/1.02) 0.99
Cardiovascular failure (inotropic at admission) 1.00 (0.98/1.02) 0.84
Co interventions
Activated Protein C 1.40 (0.59/3.29) 0.45
Stress dose steroids 1.89 (1.34/2.64) < 0.001
Protective mechanical ventilation (<8 ml/kg) 0.63 (0.45/0.89) 0.008
Restrictive fluid strategy (net fluid balance first 7 days≤ 0 ml) 0.33 (0.22/0.49) < 0.001
* Potentially confounder (p value≤ 0.10). COPD= chronic obstructive pulmonary disease, OR=odds ratio, CI= 95% confidence limit.
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The length of ICU stay was also not different in the hep-
arin group compared to the control group, p 0.59
(Table 1). A repeated analysis leaving out the APACHE
II score yielded similar results. Heparin use did not in-
fluence mortality, as it affected neither 28-day (1.23
(0.80/1.89) p = 0.34) nor 90-day mortality (1.27 (0.85/
1.89) p = 0.24).
As any possible protective effect of heparin on the oc-
currence of ALI may be due to dose, reflected by pro-
longation of the activated partial thromboplastin timeTable 3 Conditional logistic regression of mortality of patient
Mortality rate (No. deaths/t
Heparin use1 (28-day mortality) 30 (50/16
Heparin use1 (90-day mortality) 39 (64/16
1 Matched with propensity score.(aPTT), odds ratio’s for mortality were recalculated
stratified for aPTT (Table 4). In all ALI patients and in
those using heparin, a prolonged aPTT did not protect
against mortality. In patients not receiving heparin, an
aPTT< 45 seconds was found to protect against
mortality.
In an unadjusted Cox model, the risk of mortality did
not differ in patients who had received heparin com-
pared to patients who had not received heparin [hazard
ratio (HR) 0.97; 95% CI 0.67–1.40; p 0.87]. Adjustment
for propensity score did not alter risk of mortalitys with acute lung injury matched using propensity score
otal No. of patients) OR (95% CI) p
4) 1.22 (0.79/1.90) 0.36
4) 1.08 (0.73/1.59) 0.71
Table 4 Mortality over 28 days in patients with acute lung injury stratified for aPTT
Mortality rate (No. deaths/total No. of patients) OR (95% CI) p
aPTT≤ 45 (all patients) 25.4 (184/723) 0.64 (0.43/.96) 0.03
aPTT≤ 451 (patients using heparin) 31 (50/164) 0.66 (0.30/1.45) 0.26
aPTT≤ 452 (patients not using heparin) 24 (134/559) 0.54 (0.34/0.87) 0.007
Pooled results 1,2 0.57 (0.38/0.86) 0.005
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expresses cumulative survival in both groups using this
model.
The need for allogeneic blood transfusion during ICU
stay did not differ between the heparin-treated group
and the control group (44% vs. 47%, p = 0.3), nor the
mean amount of red blood cells units transfused
(0.9 ± 0.8 vs. 0.9 ± 1.0, p = 0.5).Discussion
In this retrospective, propensity matched case control
study, the use of a therapeutic dose of unfractionated
heparin was not associated with a decrease in mortality
in critically ill patients with ALI. Based on these results,
heparin does not seem to benefit patients with ALI.
These results are in contrast with previous experimen-
tal reports suggesting that intravenous heparin favorably
influences outcome in ALI [23,37,38] and also with a
prospective study, in which nebulized heparin signifi-
cantly reduced coagulation activation in the lungs of
critically ill ALI patients [28] and shortened duration of
mechanical ventilation [39].Figure 2 Cumulative survival of patients receiving heparin vs.
patients who had not received heparin based on a Cox
proportional hazard model adjusted for propensity..Our study has some important limitations. First and
foremost, sample size may have been too small to dem-
onstrate a statistically significant impact on mortality.
The study was not designed to look for an effect of hep-
arin on ALI and may have been underpowered. Indeed,
interventions studied in randomized trials with a proven
effect on outcome in ALI have required a large number
of patients [32,33]. We were not able to measure mar-
kers of inflammation in the groups and cannot comment
on the ability of intravenous heparin to influence inflam-
mation in ALI.
Second, the retrospective nature of the study design is
subject to bias. Indeed, groups differed in several base-
line characteristics. In an effort to limit confounding,
propensity analysis was performed, which resulted in
elimination of these baseline differences. Although retro-
spective analyses cannot replace the advantage of
randomization, propensity analyses may be a way of re-
ducing bias when assessing treatment effects [36]. It is
possible that some patients were already receiving hep-
arin upon ICU admission. Since APACHE II score is cal-
culated in the first 24 hours of ICU admission, one
could question the justification of using APACHE II
score when calculating propensity for heparin. However,
a repeat analysis without APACHE II score resulted in
similar findings. However, this method may still allow
for confounders unaccounted for. Another possible base-
line difference that could not be accounted for in the
propensity analysis is the dose of heparin used, as hep-
arin treatment regimen was not standardized in this
retrospective analysis. Indications for the use of heparin
were not scored and heparin dose in our ICU differs de-
pending on indication (e.g., suspected thrombo-
embolism or anticoagulant requirement due to use of
renal replacement therapy). Therefore, analyses were
repeated according to aPTT. Prolonged aPTT also did
not yield protection in ALI patients. Another explan-
ation could be the low levels of pulmonary antithrombin
(AT). The anticoagulant effects of heparin are exerted
via AT, and it may well be that AT consumption leads to
impaired actions of heparin. Previous animal studies
have demonstrated that AT combined with heparin ef-
fectively reduces acute lung injury [40].
Third, as the focus of inflammation in ALI patients is
in the lungs and nebulized heparin was protective in
ALI [28,39], it may be possible that the use of nebulized
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yielded an effect on outcome in this study, as found be-
fore [38,41]. We cannot comment on this issue, as the
intravenous route is currently standard clinical practice.
Fourth, a potential benefit of the use of heparin on
outcome may have been offset by complications of the
use of heparin, in particular bleeding. Although we were
unable to score bleeding in this retrospective analysis, it
seems unlikely that bleeding influenced mortality in this
study, given that groups did not differ in their need for
allogeneic blood transfusion.
Conclusions
In conclusion, administration of therapeutic doses of
intravenous unfractionated heparin was not associated
with reduced mortality in critically ill patients diagnosed
with ALI. Heparin treatment did not increase (bleeding)
complications.
Future investigations
In view of the limitations of our study design and the
abundant data from previous (pre-) clinical investiga-
tions, a prospective clinical trial is warranted to investi-
gate the potential of heparin treatment in critically ill
patients diagnosed with ALI. Since coagulopathy in
acute lung injury is for the most part restricted to the
lung, future investigations may include local treatment
allowing increased local efficacy while reducing the risk
on systemic bleeding.
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